| 1 |
34781244 | One-shot dual gene editing for drug-resistant pancreatic cancer therapy. | 2021 Dec |
2 |
| 2 |
34959348 | Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells. | 2021 Dec 3 |
2 |
| 3 |
32234756 | TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. | 2020 Jul 15 |
6 |
| 4 |
32427989 | Mdm4 supports DNA replication in a p53-independent fashion. | 2020 Jun |
1 |
| 5 |
32456796 | CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer. | 2020 Jul 12 |
4 |
| 6 |
33113997 | Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers. | 2020 Oct 23 |
3 |
| 7 |
31871844 | Significance of TP53 mutation in bladder cancer disease progression and drug selection. | 2019 |
1 |
| 8 |
28577130 | Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation. | 2018 Apr |
1 |
| 9 |
29115606 | DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. | 2018 Jan |
2 |
| 10 |
29301826 | p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. | 2018 Mar 15 |
1 |
| 11 |
29409053 | CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. | 2018 Apr 1 |
1 |
| 12 |
29620279 | Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres. | 2018 Jun |
3 |
| 13 |
29783721 | AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations. | 2018 May 19 |
2 |
| 14 |
29788155 | Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors. | 2018 May 1 |
1 |
| 15 |
29980405 | Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. | 2018 Aug |
1 |
| 16 |
30454541 | [Microwave Hyperthermia Combined with Gemcitabine Inhibits Proliferation
and Induces Apoptosis of Human Lung Squamous Carcinoma Cells]. | 2018 Nov 20 |
1 |
| 17 |
27888811 | The role of p53 in cancer drug resistance and targeted chemotherapy. | 2017 Jan 31 |
1 |
| 18 |
28196872 | MUC16 Regulates TSPYL5 for Lung Cancer Cell Growth and Chemoresistance by Suppressing p53. | 2017 Jul 15 |
1 |
| 19 |
28714514 | Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. | 2017 Aug |
2 |
| 20 |
28854261 | Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs). | 2017 |
5 |
| 21 |
27294865 | Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. | 2016 Jun 13 |
1 |
| 22 |
27461834 | P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. | 2016 Aug |
2 |
| 23 |
27713122 | Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. | 2016 Nov 1 |
7 |
| 24 |
25311384 | Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. | 2015 Jan |
7 |
| 25 |
25349305 | Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target. | 2015 Jan |
4 |
| 26 |
26028101 | In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS- Mediated Signalling Pathways. | 2015 |
1 |
| 27 |
26112218 | Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells. | 2015 Aug 1 |
1 |
| 28 |
26427042 | Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation. | 2015 Oct 13 |
1 |
| 29 |
26606261 | MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. | 2015 |
3 |
| 30 |
26642705 | Adenovirus-Mediated E2F-1 Gene Transfer Augments Gemcitabine-Induced Apoptosis in Human Colon Cancer Cells. | 2015 |
4 |
| 31 |
24114124 | Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. | 2014 Apr |
3 |
| 32 |
24507760 | Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer. | 2014 Feb 8 |
1 |
| 33 |
24804820 | The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells. | 2014 Jul |
1 |
| 34 |
24996846 | γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments. | 2014 Jul 4 |
1 |
| 35 |
25688502 | Evaluation of chemoradiotherapy with carbon ions and the influence of p53 mutational status in the colorectal carcinoma cell line HCT 116. | 2014 Nov-Dec |
1 |
| 36 |
23520471 | Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. | 2013 |
1 |
| 37 |
23579097 | BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents. | 2013 Jul |
2 |
| 38 |
23648290 | Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. | 2013 Aug |
2 |
| 39 |
23881403 | Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer. | 2013 Nov |
1 |
| 40 |
22041920 | Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine. | 2012 Mar |
1 |
| 41 |
22353361 | Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines. | 2012 May 1 |
3 |
| 42 |
22710877 | Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway. | 2012 Sep |
2 |
| 43 |
22903553 | sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR. | 2012 Oct |
3 |
| 44 |
23053941 | Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes. | 2012 Dec |
2 |
| 45 |
21377279 | Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells. | 2011 Jun 1 |
3 |
| 46 |
21489314 | Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer. | 2011 Apr 14 |
1 |
| 47 |
20053762 | The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. | 2010 Jan |
1 |
| 48 |
20422343 | Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation. | 2010 Aug |
1 |
| 49 |
20480521 | Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. | 2010 May 21 |
1 |
| 50 |
20558835 | Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine. | 2010 Jul |
3 |